Clinically, anti-CD19 CAR-T cells have demonstrated high efficacy in patients with relapsed/refractory B-cell malignancies, including diffuse large B-cell lymphoma (DLBCL), other aggressive B-cell lymphomas, and B-cell acute lymphoblastic leukemia (B-ALL) [26,27,28,29,30]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.